Company

Tasca Therapeutics, Inc.

Tasca Therapeutics develops small-molecule inhibitors for cancer treatment.

About

Founded in 2021, Tasca Therapeutics develops small-molecule inhibitors for oncology using a drug discovery platform that identifies lipid-binding pockets on proteins. The company is based in Boston, US. In December 2024, it raised USD 52 million in Series A funding co-led by Regeneron Ventures, Cure Ventures and Invus.

2Funding rounds

3Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in